Table 1. Demographic data at baseline and three months after COVID-19 recovery.
| Variables | Baseline† (N = 153) | 3 months† (N = 141) | P value‡ |
|---|---|---|---|
| Age (mean ± SD) | 40.8 ± 10.9 | 41.0 ± 10.5 | 0.81 |
| Body mass index (mean ± SD) | 25.6 ± 4.4 | 25.7 ± 4.4 | 0.88 |
| Marital status | 0.98 | ||
| • Single | 25 (16.3%) | 22 (15.6%) | |
| • Married or couple | 125 (81.7%) | 116 (82.3%) | |
| • Separated or divorced | 3 (2.0%) | 3 (2.1%) | |
| Education | 0.88 | ||
| • Lower than bachelor’s degree | 129 (84.3%) | 118 (83.7%) | |
| • Bachelor’s degree or upper | 24 (15.7%) | 23 (16.3%) | |
| Medical comorbidities | 29 (19%) | 28 (19.9%) | 0.84 |
| • Diabetes Mellitus | 13 (8.5%) | 13 (9.2%) | 0.83 |
| • Hypertension | 16 (10.5%) | 15 (10.6%) | 0.96 |
| • Hypercholesterolemia | 11 (7.2%) | 11 (7.8%) | 0.84 |
| Substance use | |||
| Active alcohol drinking | 26 (17.0%) | 24 (17.0%) | 0.99 |
| Active smoking | 57 (37.3%) | 51 (36.2%) | 0.85 |
| COVID-19 vaccination | 50 (32.7%) | 48 (34%) | 0.80 |
| Severity of COVID-19 | 0.94 | ||
| Pneumonia | 63 (41.2%) | 60 (42.6%) | |
| Pharyngitis | 79 (51.6%) | 70 (49.6%) | |
| Asymptomatic | 11 (7.2%) | 11 (7.8%) | |
| COVID-19 treatment | |||
| Favipiravir | 70 (45.8%) | 65 (46.1%) | 0.95 |
| Corticosteroids | 36 (23.5%) | 36 (25.5%) | 0.69 |
| Remdesivir | 10 (6.5%) | 10 (7.1%) | 0.85 |
| Tocilizumab | 5 (3.3%) | 5 (3.5%) | 0.90 |
| Oxygen supplement | 20 (13.1%) | 20 (14.2%) | 0.78 |
† Data were shown in counts (%) for categorical variables and mean ± standard deviation (SD) for continuous variables.
‡ P value for unpaired difference between two groups using chi-square test for categorical variables and independent t-test for continuous variables in order to determine the differences between baseline and the follow-up cohorts.